7th Myeloid-Directed Summit 2025, November 18-20, 2025

Conference

genOway presentation

Event
-
November 18, 2025

genOway's presentation on Wednesday, November 19, 2025 | 11 a.m. EST:

How to enhance translatability of myeloid-targeted therapies in preclinical models

  • Human immune cells are recruited, differentiate and polarize in the tumor microenvironment (TME) of genO-BRGSF-HIS mouse model based on tumor type and tumor burden
  • genO-BRGSF-HIS mice recapitulates the pathophysiology of inflammatory diseases
  • genO-BRGSF-HIS mouse model is a valuable tool to investigate immune-related adverse events induced by immunotherapies

7th Myeloid-Directed Summit 2025, November 18-20, 2025

Get in touch

Let us know how we can help

Other news & events

7th Myeloid-Directed Summit 2025, November 18-20, 2025
Conference
genOway presentation
Event
-
Nov 2025
Read on
genOway Shanghai at BIONNOVA Beijing Forum 2025
Conference
Event
-
Sep 2025
Read on
genOway Shanghai at 2025 Future Cell Therapy Executives Summit
Conference
Event
-
Sep 2025
Read on
genOway Shanghai at Bio Tonacea 2025
Conference
Event
-
Aug 2025
Read on
5th Fc-Mediated Summit 2025, July 29-31, 2025
Conference
genOway presentation
Event
-
Jul 2025
Read on
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe